Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / DSRLF - DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript


DSRLF - DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript

2024-03-15 19:25:03 ET

DiaSorin S.p.A. (DSRLF)

Q4 2023 Earnings Conference Call

March 15, 2024 10:00 AM ET

Company Participants

Carlo Rosa - Chief Executive Officer

Piergiorgio Pedron - Chief Financial Officer

Conference Call Participants

Aisyah Noor - Morgan Stanley

Maja Pataki - Kepler Cheuvreux

Hugo Salaun - BNP Paribas Exane

Shubhangi Gupta - HSBC

Odysseas Manesiotis - Berenberg

Presentation

Operator

Good afternoon, this is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin Full-Year 2023 Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]

At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir.

Carlo Rosa

Thank you, operator. Good morning, good afternoon to everybody. Welcome to the 2023 full-year results. As usual, I'm going to make some initial strategic remarks, and then the Chief Financial Officer, Piergiorgio is going to take you through the numbers.

As a general comment, let me say that 2023 was a very, very busy year. It was the second year after the acquisition of Luminex, and has been -- we completed our integration plan with the company. And we -- I would like to say that by December of last year, integration is done, the strategic role of Luminex has been defined. The senior leadership team has been set in place, the branding of Luminex has been defined. And today, Luminex is a brand that we are using just for our LTG products, whereas all IVD products, molecular and immuno, goes under DiaSorin.

From an operation point of view, we have invested heavily in our quality system, and I think it's noteworthy that we have closed the warning letter with the FDA, and we have completed our investment in manufacturing in the Chicago plant, and we are on the way to complete also the California plant where the next manufacturing will happen....

For further details see:

DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
Stock Information

Company Name: Diasorin S.R.L.
Stock Symbol: DSRLF
Market: OTC

Menu

DSRLF DSRLF Quote DSRLF Short DSRLF News DSRLF Articles DSRLF Message Board
Get DSRLF Alerts

News, Short Squeeze, Breakout and More Instantly...